There are currently 382 clinical trials in Scottsdale, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Arizona, Mayo Clinic, Mayo Clinic Scottsdale and Mayo Clinic Arizona. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06406114
Recruiting
Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/05/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Register for Updates
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717
Recruiting
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: GSK Investigational Site, Scottsdale, Arizona +1 locations
Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/05/2025
Locations: Research Site, Scottsdale, Arizona
Conditions: Acute Coronary Syndrome
Register for Updates
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
NCT06880861
Recruiting
This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
NCT06621602
Recruiting
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
08/04/2025
Locations: CND Life Sciences, Scottsdale, Arizona +1 locations
Conditions: REM Behavior Disorder, Parkinson Disease
Register for Updates
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042379
Recruiting
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Register for Updates
An Observational Study of Individuals With Isolated Dystonia
NCT07111663
Recruiting
This is an observational study in individuals with isolated (or primary) dystonia that involves more than one body region. The purpose of the study is to collect detailed information to help your physician and other researchers understand how dystonia impacts your and other patients' lives and how the disease changes over time. The study may also help researchers better understand the clinical scales that are commonly used to evaluate dystonia symptoms and how they affect various areas of life s... Read More
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
08/01/2025
Locations: Vima Site #004, Scottsdale, Arizona
Conditions: Isolated/Primary Dystonia That Affects More Than One Region of the Body
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2025
Locations: Retina Macula Institute of Arizona, Scottsdale, Arizona
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954
Recruiting
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Uveal Melanoma
Register for Updates
Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/01/2025
Locations: Ctr Dermatology and Plastic Surgery, Scottsdale, Arizona
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Advanced Prostate Cancer, Metastatic Prostate Cancer
Register for Updates
The CONFORM Pivotal Trial
NCT05147792
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Atrial Fibrillation, Stroke
Register for Updates